Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when
administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in
patients with locally advanced or metastatic basal cell carcinoma (BCC). The safety and
tolerability of CX-4945, preliminary evidence of antitumor effect, and the effect of CX-4945
treatment on the Hh signaling pathway will also be evaluated in this study.